US 12,351,625 B2
Therapeutic antibodies against osteopontin
Lawrence L. K. Leung, Hillsborough, CA (US); Michael J. Morser, San Francisco, CA (US); and Timothy Myles, Sunnyvale, CA (US)
Assigned to The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The United States Government as represented by the Department of Veterans Affairs, Washington, DC (US)
Appl. No. 17/633,797
Filed by The Board of Trustees of the Leland Stanford Junior University, Stanford, CA (US); and The United States Government as represented by the Department of Veterans Affairs, Washington, DC (US)
PCT Filed Aug. 7, 2020, PCT No. PCT/US2020/045466
§ 371(c)(1), (2) Date Feb. 8, 2022,
PCT Pub. No. WO2021/030209, PCT Pub. Date Feb. 18, 2021.
Claims priority of provisional application 62/884,818, filed on Aug. 9, 2019.
Prior Publication US 2022/0324956 A1, Oct. 13, 2022
Int. Cl. A61K 39/395 (2006.01); A61K 31/397 (2006.01); A61K 31/4184 (2006.01); A61K 31/519 (2006.01); A61K 47/00 (2006.01); A61P 35/00 (2006.01); C07K 16/00 (2006.01); C07K 16/24 (2006.01)
CPC C07K 16/24 (2013.01) [A61K 31/397 (2013.01); A61K 31/4184 (2013.01); A61K 31/519 (2013.01); A61K 47/00 (2013.01); A61P 35/00 (2018.01)] 19 Claims
 
1. An isolated antibody or an antigen-binding fragment thereof that specifically binds to osteopontin or a thrombin cleavage fragment thereof, wherein the antibody or antigen-binding fragment thereof inhibits thrombin cleavage of osteopontin or integrin binding to the thrombin cleavage fragment of osteopontin,
wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 29; a heavy chain complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:30; a heavy chain complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:31; a light chain complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:32; a light chain complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:33; and a light chain complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:34;
wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 35; a heavy chain complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:36; a heavy chain complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:37; a light chain complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:38; a light chain complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:39; and a light chain complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:40; or
wherein the antibody or antigen-binding fragment thereof comprises a heavy chain complementarity-determining region 1 (CDR-H1) comprising the amino acid sequence of SEQ ID NO: 41; a heavy chain complementarity-determining region 2 (CDR-H2) comprising the amino acid sequence of SEQ ID NO:42; a heavy chain complementarity-determining region 3 (CDR-H3) comprising the amino acid sequence of SEQ ID NO:43; a light chain complementarity-determining region 1 (CDR-L1) comprising the amino acid sequence of SEQ ID NO:44; a light chain complementarity-determining region 2 (CDR-L2) comprising the amino acid sequence of SEQ ID NO:45; and a light chain complementarity-determining region 3 (CDR-L3) comprising the amino acid sequence of SEQ ID NO:46.